Gavel striking a block on a courtroom desk with legal documents, symbolizing a high court ruling.
Sun Pharmaceutical Industries has won a legal battle in the Bombay High Court, securing an injunction against Meghmani Lifesciences. The court order prevents Meghmani from using its product mark ‘Esiraft’, following Sun Pharma’s allegations of trademark infringement related to its brand ‘Raciraft’.
The High Court found that the marks were visually and phonetically similar, raising concerns about potential consumer confusion. This decision underscores the importance of trademark protection in the pharmaceutical sector, where brand recognition plays a crucial role.
The case highlights the ongoing challenges companies face in safeguarding their intellectual property and the potential impact of trademark disputes on market competition. Sun Pharma’s successful legal action aims to protect its brand equity and prevent consumer deception.
About the Author
